Skip to main content
Toggle navigation
Login
Search
Home
Back
Favorite
0
Like
Facebook
Tweet
Print
Session 1: Lymphoma
Treatment Paradigm for 3rd Line R/R DLBCL- CAR-T, Novel Agents etc
Friday, April 22, 2022
8:30 AM – 8:50 AM
Speaker(s)
Sarah Rutherford, MD
Assistant Professor of Medicine
Weill Cornell Medicine
New York, New York
Learning Objectives:
Assess the mechanisms, safety, and efficacy of new and emerging agents for the treatment of R/RDLBCL
Evaluate emerging clinical efficacy and safety data to compare agents in development for R/RDLBCL
Devise strategies to mitigate potential adverse effects and toxicities associated with new andemerging R/R DLBCL treatments
Select and sequence PI3K and EZH2 inhibitors based on patient factors for individualized treatment of NHL
Implement strategies to manage PI3K and EZH2 inhibitor treatment-related toxicities and ensure patient-centered care
Evaluate clinical data and Real-World evidence of new CAR T cell directed therapies to devise patient treatment plans